TAMPA, Fla.--(BUSINESS WIRE)--Feb. 14, 2006--Accentia Biopharmaceuticals Inc. (NASDAQ:ABPI), a biopharmaceutical company focused on the development and commercialization of late-stage clinical respiratory and oncological products, released the results of its operations for the fiscal first quarter ended December 31, 2005. Accentia has two operating segments: specialty pharmaceuticals, and biopharmaceutical products and services. The Company also has an approximate 79% interest in Biovest International, Inc. (OTCBB:BVTI; "Biovest"), which is consolidated for reporting purposes with Accentia's product-development and market-services division.
